San­doz, Pol­phar­ma score Eu­ro­pean ap­proval for first Tysabri biosim­i­lar for mul­ti­ple scle­ro­sis

Fol­low­ing quick­ly on the heels of US biosim­i­lar ap­provals, Am­s­ter­dam-based Pol­phar­ma Bi­o­log­ics scored a Eu­ro­pean Com­mis­sion au­tho­riza­tion for its Tysabri (na­tal­izum­ab) biosim­i­lar for mul­ti­ple scle­ro­sis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER